The Neuropsychiatry of Parkinson Disease: A Perfect Storm.
Daniel Weintraub, Eugenia Mamikonyan
https://pubmed.ncbi.nlm.nih.gov/31006550/Actively Recruiting
Led by University Hospital Tuebingen · Updated on 2026-07-13
150
Participants Needed
7
Research Sites
N/A
Total Duration
This research aims to evaluate intestinal Levodopa plus entacapone therapy Lecigon4 in patients with Parkinsons disease who require this treatment based on existing guidelines. The study is a Phase III randomized controlled trial comparing Lecigon4 to the best available oral medication. The primary goal is to assess whether Lecigon4 is superior in reducing hyperdopaminergic symptoms measured by the Ardouin Behavioral Scale after six months. Participants are randomly assigned to one of two groups those continuing best oral medication and those receiving Lecigon4 as an intestinal gel combining levodopa, carbidopa, and entacapone. The trial uses a parallel group design with a waiting list component. Treatment is given according to established dosing criteria and patients are followed for at least six months to monitor effects. During the study, participants undergo regular assessments including behavioral evaluations with the Ardouin Behavioral Scale to track hyperdopaminergic syndrome changes. Safety and adherence to therapy are monitored throughout. The trial excludes patients with severe cognitive impairment or other contraindications. Total participation covers screening, treatment, and follow-up up to six months, with the primary outcome measured at that time.
CONDITIONS
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
D
Daniel Weiss, Prof
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital Tuebingen
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 months
Participants receive either intestinal Lecigon4 therapy or continue best oral medication as assigned.
Regular visits during treatment period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Daniel Weintraub, Eugenia Mamikonyan
https://pubmed.ncbi.nlm.nih.gov/31006550/Eugénie Lhommée, Lars Wojtecki, Virginie Czernecki...
https://pubmed.ncbi.nlm.nih.gov/29452685/Daniel Weiss, Georg Ebersbach, Jens Carsten Möller...
https://pubmed.ncbi.nlm.nih.gov/36087571/Daniel Weiss, Jens Volkmann, Alfonso Fasano...
https://pubmed.ncbi.nlm.nih.gov/34235776/Paolo Calabresi, Massimiliano Di Filippo, Veronica Ghiglieri...
https://pubmed.ncbi.nlm.nih.gov/20880751/Daniel Weintraub, Juergen Koester, Marc N Potenza...
https://pubmed.ncbi.nlm.nih.gov/20457959/Daniel Weiss, Wolfgang H Jost, József Attila Szász...
https://pubmed.ncbi.nlm.nih.gov/40129359/University Hospital Tuebingen
Lead Sponsor